FDA Clearance For ClearPoint Neuro Laser Device

Global therapy-enabling platform company, ClearPoint Neuro (Nasdaq: CLPT) has been granted FDA 501(k) clearance for a laser it intends to commercialize worldwide.

The laser will be marketed as the ClearPoint Prism™ Neuro Laser Therapy System and is being hailed as a “new innovation in the space of laser interstitial thermal therapy”.

Laser ablation offers minimally-invasive and powerful treatments for a variety of neurological diseases.

Highlights

  • ClearPoint Neuro has exclusive global rights to commercialize the magnetic resonance guided laser interstitial thermal therapy system for neuro applications.
  • The system is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy under 3.0T magnetic resonance imaging (MRI) guidance.
  • The ClearPoint Neuro Navigation System has been used for over a decade in the United States and Europe to treat brain tumors, radiation necrosis and epileptic foci.
  • ClearPoint continues to deliver innovation to the neurosurgery and spine community through its team and expert partners.

ClearPoint’s laser offers a number of exciting technical innovations that are expected to make laser interstitial thermal therapy simpler and more accessible to surgeons and their patients.

About the Author

FDA Clearance For ClearPoint Neuro Laser Device

Editor Investors Prism